Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in ... refractory or relapsed advanced including epithelial ovarian cancer, colorectal, gastric, hepatocellular, ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in ... refractory or relapsed advanced including epithelial ovarian cancer, colorectal, gastric, hepatocellular, ...

Long-Term Safety of Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial ASCO 2023: Safety Analysis by UGT1A1 Status of TROPHY-U-01 Cohort 1, a Phase 2 ...

the most common form of bladder cancer. The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or ...

The duo of TAR-200 and cetrelimab was safe and efficacious in the neoadjuvant setting for certain patients with muscle-invasive bladder cancer.

Gene Expression Profile and Immune Cell Profile in the Non-Muscle Invasive Bladder Cancer Tumour Microenvironment IBCN 2023: SURE-01: Interim Results of a Phase 2 Study of Neoadjuvant Sacituzumab ...

Trastuzumab deruxtecan [T-DXd; Enhertu] was also approved in 2019. Then in 2020, we got sacituzumab govitecan [Trodelvy] for a triple-negative breast cancer. In 2022, T-DXd expanded indication in HER2 ...

Bladder cancer can be curable, and the likelihood of cure is higher if it is diagnosed at an early stage. Without treatment, bladder cancer does not go away on its own, and treatment is associated ...

She is also the chief medical officer of the lab consultancy firm Blood Associates, LLC. Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the hollow organ in your ...

In the study, Trodelvy (sacituzumab govitecan) met its objective of ... approved indication of triple-negative breast cancer (TNBC) and bladder cancer, and justify the $21 billion the company ...